Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis

Nephrology

Volumn 19, Issue 5, 2014, Pages 266-274

  Roger, Simon D ^a   Kolmakova, Elena ^b   Fung, Maple ^c   Malecki, Robert ^d   Vinhas, José ^e   Dellanna, Frank ^f   Thomas, Mark ^g   Manamley, Nick ^h   Ferenczi, Sándor ⁱ  

^a Renal Research   (Australia)

^b NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

^c AMGEN INC   (United States)

^d Miedzyleski Szpital Specjalistyczny w Warszawa   (Poland)

^e HOSPITAL DE SÃO BERNARDO   (Portugal)

^f Gemeinschaftspraxis Karlstrasse   (Germany)

^g BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^h AMGEN LTD   (United Kingdom)

ⁱ Petz Aladar Megyei Oktato Korhaz B Braun Avitum Hungary No 11 Dialysis Center   (Hungary)

Author keywords

anaemia; chronic kidney failure; darbepoetin alfa; haemoglobin; randomized controlled trial

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ANTIANEMIC AGENT; BIOLOGICAL MARKER; ERYTHROPOIETIN; HEMOGLOBIN;

AGED; ANEMIA; ARTICLE; ASTHENIA; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; ADULT; ANALOGS AND DERIVATIVES; AUSTRALIA; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; EUROPE; METABOLISM; MEXICO; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RENAL INSUFFICIENCY, CHRONIC; TIME; TREATMENT OUTCOME; UPREGULATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; AUSTRALIA; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; EUROPE; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MEXICO; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; YOUNG ADULT;

EID: 84898940485     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12214     Document Type: Article

References (12)

1. Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat. Biotechnol. 2003; 21: 414-421.
2. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA,. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp. Hematol. 2003; 31: 290-299.
3. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Intern. Med. 2006; 145: 247-254.
4. Pergola PE, Gartenberg G, Fu M, Sun S, Wolfson M, Bowers P,. A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia. Clin. J. Am. Soc. Nephrol. 2010; 5: 598-606.
5. Spinowitz B, Germain M, Benz R, et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2008; 3: 1015-1021.
6. Pergola PE, Gartenberg G, Fu M, Wolfson M, Rao S, Bowers P,. A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia. Clin. J. Am. Soc. Nephrol. 2009; 4: 1731-1740.
7. Levin NW, Fishbane S, Canedo FV, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: A randomised non-inferiority trial (MAXIMA). Lancet 2007; 370: 1415-1421.
8. Sulowicz W, Locatelli F, Ryckelynck JP, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin. J. Am. Soc. Nephrol. 2007; 2: 637-646.
9. Roger SD, Locatelli F, Woitas RP, et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol. Dial. Transplant. 2011; 26: 3980-3986.
10. Kessler M, Martinez-Castelao A, Siamopoulos KC, et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodial. Int. 2010; 14: 233-239.
11. Macdougall IC, Walker R, Provenzano R, et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: Results of a randomized clinical trial. Clin. J. Am. Soc. Nephrol. 2008; 3: 337-347.
12. Derebail VK, Nachman PH, Key NS, et al. Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. Kidney Int. 2011; 80: 992-999.